Drug Trial Radar · NCT07750041
A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Aug 30, 2026
Primary completion
Dec 31, 2027
Study completion Aug 30, 2029
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study constitutes an open-label, multi-cohort, multi-center Phase Ib/II clinical study, developed to assess the safety, tolerability, and therapeutic efficacy of SYS6090 injection when administered in combination with bevacizumab, or in triple combination with bevacizumab and chemotherapy, among patients diagnosed with advanced colorectal cancer.
Conditions
- Unresectable Advanced or Metastatic Colorectal Cancer
Interventions
SYS6090 (Fixed Dose Level A) + bevacizumabDrug
Participants will receive intravenous SYS6090 at fixed dose level A combined with intravenous bevacizumab, administered per cycle schedule specified in study protocol, for advanced/palliative unresectable pMMR/MSS colorectal cancer.
SYS6090 (Fixed Dose Level B ) + bevacizumabDrug
Participants will receive intravenous SYS6090 at fixed dose level B plus intravenous bevacizumab per protocol-defined cycle schedule for unresectable advanced pMMR/MSS colorectal cancer.
SYS6090 RP2D + bevacizumab +mFOLFOX6Drug
Participants will receive intravenous SYS6090 at RP2D plus intravenous bevacizumab combined with standard mFOLFOX6 chemotherapy regimen (oxaliplatin, leucovorin, fluorouracil), administered per protocol-defined cycle schedule for unresectable advanced pMMR/MSS colorectal cancer.
SYS6090 RP2D + bevacizumabDrug
Participants will receive intravenous SYS6090 at RP2D plus intravenous bevacizumab, administered per protocol-defined cycle schedule for unresectable advanced pMMR/MSS colorectal cancer.
RegorafenibDrug
Oral regorafenib monotherapy as standard control for metastatic pMMR/MSS colorectal cancer.
SYS6090 PR2D+ bevacizumab + FOLFOXIRIDrug
Participants will receive intravenous SYS6090at RP2D plus intravenous bevacizumab combined with FOLFOXIRI triple chemotherapy (oxaliplatin, irinotecan, leucovorin, fluorouracil) per study cycle schedule for metastatic pMMR/MSS colorectal cancer.
bevacizumab + FOLFOXIRIDrug
Participants will receive intravenous bevacizumab combined with FOLFOXIRI triple chemotherapy (oxaliplatin, irinotecan, leucovorin, fluorouracil) per study cycle schedule for metastatic pMMR/MSS colorectal cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 Dose (RP2D), Safety and TolerabilityTime frame: up to approximately 3 years after the first enrollment
- Objective Response Rate (ORR) assessed per RECIST v1.1Time frame: up to approximately 3 years after the first enrollment
- Progression-Free Survival (PFS) assessed per RECIST v1.1Time frame: up to approximately 3 years after the first enrollment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fujian Cancer Hospital
Fujian, Fuzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.